# AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)

> **NCT07640737** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Aurigene Discovery Technologies Limited** · enrollment: 30 (estimated)

## Conditions studied

- Neuroendocrine (NE) Tumors
- Advanced NET of GI Origin

## Interventions

- **DRUG:** AUR103 Calcium

## Key facts

- **NCT ID:** NCT07640737
- **Lead sponsor:** Aurigene Discovery Technologies Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-01-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07640737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07640737, "AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07640737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*